Monday, March 14, 2016
Bristol-Myers Squibb and LabCentral, an innovative, shared laboratory space designed as a launch pad for life-sciences and biotech startups, have announced an agreement in which Bristol-Myers Squibb has become a LabCentral platinum sponsor. Bristol-Myers Squibb can nominate up to two innovative life sciences and biotech startup companies per year to take up residence in LabCentral’s Kendall Square facilities. The 2016 nomination process for Bristol-Myers Squibb-sponsored Golden Tickets will launch by the end of the first quarter.
The New York Genome Center and IBM are collaborating to create a comprehensive and open repository of genetic data to accelerate cancer research and scale access to precision medicine using cognitive insights from IBM Watson. Analyzing this data alongside the medical community’s growing knowledge about cancer could help accelerate the ability of doctors to deliver personalized treatment to individual patients.
Andrew Lloyd & Associates (ALA), an international public relations group for companies and organizations working in life sciences and innovative technologies, and Adebiotech, an independent cross-disciplinary think-tank for biotechnology in France, have signed a partnership agreement to promote interdisciplinary discussion and innovation in the field of biotechnology. In particular, this partnership aims to raise awareness of Adebiotech’s activities amongst specialist audiences interested in developments concerning human and animal health, the environment, energy, food processing, cosmetics, processes and industrial systems, amongst others.
The breast cancer treatment pipeline’s exceptional levels of activity and innovation, with a staggering 1,050 drugs in active development across all stages and 347 first-in-class programs, may significantly alter the clinical and commercial landscape of the disease market over the next decade, according to business intelligence provider GBI Research.
Seven of the world’s largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and effective therapies for Parkinson’s.
JDRF, a global organization funding and advocating for type 1 diabetes (T1D) research, and Sanofi U.S. Services, a subsidiary of Sanofi, have entered into new agreements with four research organizations under their joint research collaboration to support development of glucose responsive insulins (GRIs), an alternate class of therapies that is expected to improve the treatment of insulin-dependent diabetes, particularly T1D.